Reply to comments from Paz and Shinfeld to article entitled ‘Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: a single-centre real-world experience’
نویسندگان
چکیده
OBJECTIVE The coronary sinus Reducer is a recently introduced device to treat patients with severe angina symptoms refractory to optimal medical therapy and not amenable for conventional revascularisation. We aimed to assess the safety and efficacy of the Reducer in a real-world cohort of patients with refractory angina. METHODS This is a single-centre retrospective registry. Patients with severe angina symptoms, objective evidence of myocardial ischaemia using any adequate non-invasive modality and without options for conventional revascularisation were regarded eligible for Reducer implantation. RESULTS Twenty-three patients (74 % male, mean age 70 ± 8 years, 91.3 % previous bypass surgery, 82.6 % previous percutaneous intervention, 47.8 % previous myocardial infarction, 52.2 % diabetes mellitus) underwent Reducer implantation. The safety endpoint (successful implantation of the first device without device-related adverse events) was met in all patients. After a median follow-up of 9 (8-14) months the efficacy (any reduction in Canadian Cardiovascular Society (CCS) class and revascularisation-free survival) was reached in 17 patients (74 %): 8 patients (34.8 %) improved by 1 CCS class, 7 (30.4 %) by 2 CCS classes and 2 (8.7 %) by 3 CCS classes. One patient died 4 months after implantation because of progressive heart failure (not associated with Reducer implantation). CONCLUSION In this single-centre real-world experience, Reducer implantation was safe and demonstrated excellent clinical efficacy in the treatment of refractory angina at mid-term follow-up.
منابع مشابه
The coronary sinus reducer for the treatment of refractory angina
We were very interested to read the recently published manuscript ‘Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single-centre real-world experience’ by Masieh Abawi et al. [1]. Some people make a mistake and compare the coronary sinus reducer (CSR) with the Beck procedure (Beck operation), but actually the Beck procedure has almost nothi...
متن کاملNonconventional therapeutic modalities in refractory angina pectoris
Abstract Despite sophisticated conventional medical treatment and the continued development and improvement of coronary revascularization modalities in recent years, a significant number of patients still suffer from refractory angina pectoris and cannot be successfully managed. Advances in therapeutic options have led to an increase in the average of life expectancy even in such ...
متن کاملEvaluation of the efficacy and safety of rituximab in patients with refractory pemphigus vulgaris
Background: Recently, rituximab has been successfully used for the treatment of pemphigus family, the main subtype of which is pemphigus vulgaris (PV). The aim of this study was to determine the efficacy and safety of rituximab in refractory PV. Methods: In an observational study extending from November 2014 to February 2016, 30 patients with refractory PV were treated with rituximab. Response ...
متن کاملCoronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study.
OBJECTIVES This study sought to evaluate the safety of the Coronary Sinus Reducer (Neovasc Medical, Inc., Or Yehuda, Israel) as a potential alternate therapy for patients with refractory angina who are not candidates for conventional revascularization procedures. BACKGROUND Increased coronary sinus (CS) pressure can reduce myocardial ischemia by redistribution of blood from nonischemic to isc...
متن کامل